Elite Journal of HIV. Volume 1 Issue 1(2023), Pp. 43-54
https://epjournals.com/journals/EJHIV

Ceruloplasmin and HIV-Associated Hepatobiliary Disorders: A Review

*Emmanuel Ifeanyi Obeagu[1] and Getrude Uzoma Obeagu[2]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda

[2]School of Nursing Science, Kampala International University, Uganda

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Hepatobiliary disorders represent significant comorbidities in individuals infected with the human immunodeficiency virus (HIV), contributing to morbidity and mortality worldwide. Ceruloplasmin, a multifunctional glycoprotein primarily synthesized in the liver, has emerged as a focal point in understanding the pathogenesis and management of HIV-associated liver dysfunction. This review delves into the intricate relationship between ceruloplasmin and HIV-associated hepatobiliary disorders, exploring its role as a potential biomarker and therapeutic target in these conditions. Ceruloplasmin exerts its influence through its involvement in copper metabolism, iron homeostasis, and antioxidant defense mechanisms. Dysregulation of ceruloplasmin levels in HIV-infected individuals may occur due to direct viral effects on hepatocytes, immune-mediated inflammation, and the hepatotoxicity associated with antiretroviral therapy (ART). Elevated serum ceruloplasmin levels have been observed in HIV-infected individuals with liver dysfunction, suggesting its potential as a diagnostic biomarker for hepatobiliary disorders. Moreover, ceruloplasmin levels may correlate with disease severity and prognosis, providing valuable insights into the progression and outcomes of HIV-associated liver disease. Optimizing ART regimens to minimize hepatotoxicity and oxidative stress may help maintain ceruloplasmin homeostasis and mitigate liver damage in HIV-infected individuals.

Keywords: *Ceruloplasmin, HIV, Hepatobiliary Disorders, Liver Dysfunction, Hepatitis, Antiretroviral Therapy, Oxidative Stress*

Citation: Obeagu EI, Obeagu GU. Ceruloplasmin and HIV-Associated Hepatobiliary Disorders: A Review. Elite Journal of HIV, 2023; 1(1): 43-54

Introduction

Hepatobiliary disorders pose significant challenges in the management of individuals living with human immunodeficiency virus (HIV), constituting a notable cause of morbidity and mortality globally. Among the myriad complications associated with HIV infection, liver dysfunction stands out as a critical concern, with a spectrum of manifestations ranging from hepatitis to end-stage liver disease. Ceruloplasmin, a versatile glycoprotein predominantly synthesized in the liver, has garnered attention for its potential role in HIV-associated liver dysfunction. Beyond its canonical function in copper transport and antioxidant defense, ceruloplasmin has been implicated in various physiological processes, including iron metabolism, angiogenesis, and inflammatory modulation. Given its diverse functions and hepatic origin, ceruloplasmin represents a compelling candidate for elucidating the pathophysiology of HIV-associated hepatobiliary disorders. The pathogenesis of liver dysfunction in HIV-infected individuals is multifactorial, encompassing direct viral effects, immune-mediated inflammation, coinfections (e.g., viral hepatitis), and adverse effects of antiretroviral therapy (ART). Ceruloplasmin may be intricately involved in these processes, influencing the progression and severity of liver disease through its antioxidant properties, modulation of inflammatory responses, and potential interactions with viral pathogens. Understanding the specific mechanisms by which ceruloplasmin contributes to liver pathology in the context of HIV infection is crucial for developing targeted interventions.[1-20]

Moreover, the diagnostic and prognostic implications of ceruloplasmin in HIV-associated hepatobiliary disorders warrant exploration. Elevated serum ceruloplasmin levels have been reported in HIV-infected individuals with liver dysfunction, suggesting its potential utility as a biomarker for hepatobiliary disease progression. Furthermore, ceruloplasmin levels may correlate with disease severity and prognosis, providing valuable insights into the natural history of HIV-associated liver disease and informing clinical decision-making. In addition to its diagnostic potential, ceruloplasmin may serve as a therapeutic target for mitigating liver damage in HIV-infected individuals. Strategies aimed at modulating ceruloplasmin expression or activity could offer novel approaches for managing hepatobiliary disorders in this population. Optimization of ART regimens to minimize hepatotoxicity and oxidative stress may represent an adjunctive strategy for preserving ceruloplasmin homeostasis and ameliorating liver injury.[21-30]

This review aims to synthesize existing literature on the role of ceruloplasmin in HIV-associated hepatobiliary disorders, encompassing its function, regulation, diagnostic utility, and therapeutic potential.

Ceruloplasmin Function and Regulation

Ceruloplasmin, a multifunctional glycoprotein primarily synthesized in the liver, plays a pivotal role in various physiological processes, including copper metabolism, iron homeostasis, and antioxidant defense mechanisms.[31] Its multifaceted functions make it indispensable for maintaining cellular integrity and overall health. Ceruloplasmin serves as the principal copper-carrying protein in the bloodstream, facilitating the transport of copper ions from the liver to

peripheral tissues. Copper is an essential micronutrient involved in numerous enzymatic reactions, including those crucial for energy production, neurotransmitter synthesis, and connective tissue formation. Ceruloplasmin ensures the efficient distribution of copper throughout the body, thereby supporting vital biological processes. In addition to its role in copper transport, ceruloplasmin influences iron metabolism by facilitating the conversion of ferrous iron (Fe^2+) to its ferric form (Fe^3+). This enzymatic activity, known as ferroxidase activity, promotes the incorporation of iron into transferrin, the primary iron transport protein in the bloodstream. By enhancing iron binding to transferrin, ceruloplasmin contributes to the regulation of systemic iron levels, thereby preventing iron toxicity and maintaining iron homeostasis.

Ceruloplasmin exerts potent antioxidant effects through its ability to scavenge free radicals and mitigate oxidative stress.[32] Free radicals, generated as byproducts of cellular metabolism or in response to environmental stressors, can cause cellular damage by oxidizing lipids, proteins, and DNA. Ceruloplasmin acts as a ferroxidase enzyme, converting toxic ferrous ions (Fe^2+) into less reactive ferric ions (Fe^3+), thereby preventing the generation of harmful hydroxyl radicals through the Fenton reaction. This antioxidant function helps protect cells and tissues from oxidative damage, mitigating the risk of oxidative stress-related diseases. Ceruloplasmin synthesis and secretion are tightly regulated at the transcriptional and post-transcriptional levels. Hormonal factors, such as estrogen and growth hormone, have been implicated in the regulation of ceruloplasmin expression, with estrogen stimulating ceruloplasmin synthesis in the liver. Additionally, inflammatory mediators, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), can induce ceruloplasmin production in response to acute-phase reactions. Genetic polymorphisms in the ceruloplasmin gene (CP) may also influence ceruloplasmin levels and activity, potentially impacting individual susceptibility to copper-related disorders and oxidative stress-related diseases.

Role of Ceruloplasmin in HIV-Associated Hepatobiliary Disorders

The role of ceruloplasmin in HIV-associated hepatobiliary disorders is multifaceted, encompassing its involvement in the pathogenesis, diagnosis, and management of liver dysfunction in individuals living with HIV. Ceruloplasmin may influence the pathogenesis of liver dysfunction in HIV-infected individuals through several mechanisms. Firstly, HIV infection itself can directly affect hepatocytes, leading to hepatic inflammation, fibrosis, and ultimately, cirrhosis. Ceruloplasmin's antioxidant properties are particularly relevant in this context, as oxidative stress plays a pivotal role in mediating liver injury in HIV-associated hepatobiliary disorders. By scavenging free radicals and mitigating oxidative damage, ceruloplasmin may help protect hepatocytes from the deleterious effects of HIV-induced inflammation and immune dysregulation. Elevated serum ceruloplasmin levels have been observed in HIV-infected individuals with liver dysfunction, suggesting a potential association between ceruloplasmin and the progression of hepatobiliary disease. Ceruloplasmin levels may serve as a biomarker for disease severity and prognosis, providing valuable insights into the natural history of HIV-associated liver disease and informing clinical decision-making. Furthermore, ceruloplasmin's role in modulating

inflammatory responses and oxidative stress may contribute to its influence on disease progression in this population.[33-47]

Ceruloplasmin levels have been proposed as a diagnostic biomarker for hepatobiliary disorders in HIV-infected individuals. Elevated serum ceruloplasmin levels have been reported in patients with liver dysfunction, suggesting its potential utility as a non-invasive marker for identifying individuals at risk of developing hepatobiliary complications. Incorporating ceruloplasmin measurements into routine clinical assessments may help clinicians detect liver dysfunction at an early stage, enabling timely intervention and management. Modulating ceruloplasmin levels could represent a novel therapeutic approach for managing HIV-associated hepatobiliary disorders. Pharmacological interventions targeting ceruloplasmin expression or activity, such as antioxidants or ceruloplasmin-stabilizing agents, may help mitigate liver damage and improve outcomes in HIV-infected individuals. Additionally, optimizing antiretroviral therapy regimens to minimize hepatotoxicity and oxidative stress could help preserve ceruloplasmin homeostasis and alleviate liver injury in this population.[48-62]

Diagnostic and Prognostic Implications

Diagnostic and prognostic implications of ceruloplasmin in HIV-associated hepatobiliary disorders are of significant interest in clinical practice, offering insights into disease severity, progression, and outcomes. Elevated serum ceruloplasmin levels have been observed in HIV-infected individuals with liver dysfunction, suggesting its potential utility as a diagnostic biomarker for hepatobiliary disorders. Ceruloplasmin levels may rise in response to hepatocellular injury, inflammation, and oxidative stress, reflecting underlying liver pathology. Incorporating ceruloplasmin measurements into routine clinical assessments could enhance the diagnostic armamentarium for identifying liver dysfunction in HIV-infected patients, particularly in resource-limited settings where sophisticated imaging modalities may be unavailable. Ceruloplasmin levels may correlate with the severity of liver disease in HIV-infected individuals, providing valuable prognostic information. Studies have suggested that higher ceruloplasmin levels are associated with more advanced liver fibrosis, cirrhosis, and hepatocellular carcinoma in HIV-infected patients. Monitoring changes in ceruloplasmin levels over time may help clinicians assess disease progression and tailor management strategies accordingly. Additionally, ceruloplasmin levels could serve as a prognostic indicator for predicting long-term outcomes, such as liver-related morbidity and mortality, in HIV-associated hepatobiliary disorders. Serial measurement of ceruloplasmin levels may also be useful for monitoring treatment response in HIV-infected individuals with hepatobiliary disorders. Changes in ceruloplasmin levels following initiation of antiretroviral therapy or other therapeutic interventions may reflect improvements or worsening of liver function. Integrating ceruloplasmin monitoring into clinical practice could facilitate early identification of treatment failures or adverse effects, enabling timely adjustments to management strategies and optimization of patient outcomes. Ceruloplasmin levels may serve as a marker for stratifying the risk of hepatobiliary complications in HIV-infected individuals. Elevated ceruloplasmin levels may indicate increased susceptibility to liver dysfunction, progression to cirrhosis, or development of hepatocellular carcinoma. Stratifying patients based on ceruloplasmin

levels could help identify those at higher risk of adverse outcomes, allowing for targeted interventions and closer monitoring to mitigate the risk of disease progression and complications.[63-67]

Therapeutic Considerations

Therapeutic considerations regarding ceruloplasmin in the context of HIV-associated hepatobiliary disorders encompass strategies aimed at modulating ceruloplasmin levels, optimizing antiretroviral therapy (ART), and mitigating oxidative stress to preserve liver function and improve clinical outcomes in affected individuals. Pharmacological interventions targeting ceruloplasmin expression or activity may hold promise as adjunctive therapies for managing HIV-associated liver dysfunction.[68] Agents that enhance ceruloplasmin synthesis or stabilize its enzymatic activity could potentially mitigate liver injury and promote hepatocyte repair. Additionally, antioxidants and anti-inflammatory agents may help counteract oxidative stress and inflammation, thereby preserving ceruloplasmin homeostasis and ameliorating liver damage. Optimizing antiretroviral therapy regimens is crucial for minimizing hepatotoxicity and oxidative stress in HIV-infected individuals with hepatobiliary disorders. Certain antiretroviral drugs, particularly those belonging to the class of nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs), have been associated with hepatotoxic effects and mitochondrial dysfunction. Switching to alternative antiretroviral agents with a more favorable hepatic safety profile may be necessary in patients experiencing liver-related adverse effects or drug-induced liver injury. Personalized selection of ART regimens based on individual patient factors, including liver function, comorbidities, and medication tolerability, is essential to optimize therapeutic efficacy and minimize hepatotoxicity.

Lifestyle modifications, including dietary changes, alcohol cessation, and weight management, play a critical role in the management of HIV-associated hepatobiliary disorders.[69] Dietary interventions aimed at reducing oxidative stress and supporting liver function, such as increasing consumption of antioxidant-rich foods (e.g., fruits, vegetables, nuts) and limiting intake of processed foods and trans fats, may complement pharmacological therapies targeting ceruloplasmin and oxidative stress. Additionally, avoiding excessive alcohol consumption and maintaining a healthy body weight are essential for preventing liver damage and promoting overall hepatobiliary health in HIV-infected individuals. Management of comorbidities, such as viral hepatitis coinfections (e.g., hepatitis B virus [HBV], hepatitis C virus [HCV]), metabolic syndrome, and substance abuse, is integral to the comprehensive care of HIV-infected individuals with hepatobiliary disorders. Coordinated multidisciplinary care involving hepatologists, infectious disease specialists, nutritionists, and mental health professionals is essential for addressing the complex medical, psychosocial, and behavioral aspects of these comorbid conditions. Timely screening, diagnosis, and treatment of comorbidities are crucial for optimizing liver health outcomes and reducing the burden of HIV-associated liver disease.

Conclusion

Ceruloplasmin emerges as a central player in the intricate interplay between HIV infection and hepatobiliary disorders, exerting multifaceted effects on disease pathogenesis, diagnosis, and management. Through its roles in copper metabolism, iron homeostasis, and antioxidant defense mechanisms, ceruloplasmin influences various aspects of liver function and integrity, making it a promising biomarker and therapeutic target in HIV-associated liver dysfunction. Diagnostic implications of ceruloplasmin include its potential utility as a biomarker for identifying hepatobiliary disorders in HIV-infected individuals. Elevated serum ceruloplasmin levels may serve as an indicator of liver dysfunction, facilitating early detection and intervention. Furthermore, ceruloplasmin levels may correlate with disease severity and prognosis, providing valuable prognostic information and guiding clinical decision-making. Therapeutic considerations regarding ceruloplasmin encompass strategies aimed at modulating its levels, optimizing antiretroviral therapy, and implementing lifestyle modifications to preserve liver function and improve clinical outcomes. Pharmacological interventions targeting ceruloplasmin expression or activity, along with lifestyle modifications aimed at reducing oxidative stress and supporting liver health, represent promising avenues for managing HIV-associated hepatobiliary disorders.

References

1. Vachon ML, Perumalswami P, Dieterich DT. Hepatobiliary manifestations of human immunodeficiency virus. Schiff's Diseases of the Liver. 2011:1060-1082.
2. Neuman MG, Monteiro M, Rehm J. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses. Substance use & misuse. 2006;41(10-12):1395-1463.
3. Kuczkowski KM. Human immunodeficiency virus in the parturient. Journal of clinical anesthesia. 2003;15(3):224-233.
4. Perovic O, Singh A. Nosocomial Infections in patients with human immunodeficiency virus (HIV). In HIV Infection in the Era of Highly Active Antiretroviral Treatment and Some of Its Associated Complications 2011. IntechOpen.
5. Cordie A, Gaber Y, AbdAllah M, Vergori A, Kharono B, Omran S, Afify S, Karkouri M, Chakroun M, Musa S, Moorhouse M. Gastrointestinal manifestations of human immunodeficiency virus and coronavirus disease 2019: Understanding the intersecting regions between the two epidemics. Arab Journal of Gastroenterology. 2021;22(2):75-87.
6. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
7. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.
8. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.

Citation: Obeagu EI, Obeagu GU. Ceruloplasmin and HIV-Associated Hepatobiliary Disorders: A Review. Elite Journal of HIV, 2023; 1(1): 43-54

9. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
10. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
11. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
12. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
13. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
14. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
15. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.
16. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
17. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
18. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
19. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.

20. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
21. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
22. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
23. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
24. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
25. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
26. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
27. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
28. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
29. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis,

Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.

30. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf
31. Linder MC. Ceruloplasmin and other copper binding components of blood plasma and their functions: an update. Metallomics. 2016;8(9):887-905.
32. Shukla N, Maher J, Masters J, Angelini GD, Jeremy JY. Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor? Atherosclerosis. 2006;187(2):238-250.
33. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
34. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
35. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
36. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** 10.32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
37. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
38. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies

Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.

39. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
40. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
41. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
42. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETRQVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160**.** links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf.
43. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
44. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI: 10.22192/ijcrcps.2019.06.12.004 links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.
45. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.
46. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33. links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.
47. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-910. https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma.EMMA2.pdf.
48. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.

Citation: Obeagu EI, Obeagu GU. Ceruloplasmin and HIV-Associated Hepatobiliary Disorders: A Review. Elite Journal of HIV, 2023; 1(1): 43-54

49. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research,* 2018; 1 (2):08-14. https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf.
50. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-830.
51. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-189.
52. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023; 3 (1): 7-12.
53. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-11.
54. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-271.
55. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. Int. J. Curr. Res. Med. Sci. 2018;4(2):104-108.
56. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-66.
57. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).
58. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.
59. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
60. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. Medicine (Baltimore). 2023;102(49): e36599. doi: 10.1097/MD.0000000000036599. PMID: 38065920; PMCID: PMC10713174.

61. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Medicine (Baltimore). 2023;102(47): e36342. doi: 10.1097/MD.0000000000036342. PMID: 38013335; PMCID: PMC10681551.
62. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore). 2023;102(47): e35910. doi: 10.1097/MD.0000000000035910. PMID: 38013350; PMCID: PMC10681510.
63. Nallagangula KS, Nagaraj SK, Venkataswamy L, Chandrappa M. Liver fibrosis: a compilation on the biomarkers status and their significance during disease progression. Future science OA. 2017;4(1): FSO250.
64. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine (Baltimore). 2023;102(46): e36166. doi: 10.1097/MD.0000000000036166. PMID: 37986340; PMCID: PMC10659731.
65. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR,
66. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):14-25.
67. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. Int. J. Adv. Multidiscip. Res. 2023;10(10):56-62.
68. Ianiro G, Niro A, Rosa L, Valenti P, Musci G, Cutone A. To Boost or to Reset: The Role of Lactoferrin in Energy Metabolism. International Journal of Molecular Sciences. 2023;24(21):15925.
69. Bavaro DF, Laghetti P, Poliseno M, De Gennaro N, Di Gennaro F, Saracino A. A step closer to the “Fourth 90”: A practical narrative review of diagnosis and management of nutritional issues of people living with HIV. Diagnostics. 2021;11(11):2047.